Holger Reithinger Joins Forbion Capital

Holger Reithinger has joined Forbion Capital Partners as a partner and head of the firm’s new Munich office. He previously was with Global Life Science Ventures.

PRESS RELEASE

Forbion Capital Partners today announced the opening of its new offices in Munich, Germany and the appointment of Dr. Holger Reithinger, as a new Partner at Forbion. Holger will be the core of Forbion’s new Munich-based team. Holger joins Forbion from Global Life Science Ventures with 13 years of experience in life science venture capital.



The Forbion team has always been very active in Germany with successful investments in e.g. Rhein Biotech, Impella Cardio Systems and Alantos Pharmaceuticals. The opening of the Munich office and hiring of Holger will further strengthen the inroads to the German speaking countries and will thus contribute to Forbion’s growing European deal flow. The expansion of its European presence is driven by a steady growth of funds under management based on its strong track record built in recent years. Most recently, Forbion procured (partial) exits for its investments in PanGenetics (sold to Abbott), Argenta Discovery’s operations (sold to Galapagos) and Fovea Pharmaceuticals (sold to Sanofi Aventis).



Commenting on the developments, Bart Bergstein, Managing Partner at Forbion said: “The opening of the new office in Munich is a logical step to further growth of Forbion. Sufficient critical mass is becoming increasingly important in a market where fewer, yet bigger VC players will be serving the European life sciences market. We are very excited to have Holger join our team. We have known Holger for years and he is definitely one of the most experienced life sciences investors in Germany”.



On joining the Forbion team, Dr. Reithinger commented: “I am thrilled to join a young and entrepreneurial team of experienced life science investors with a solid track record and a strong backing from a variety of well-known international limited partners. In today’s market, where further consolidation within the VC industry is expected, Forbion is well positioned to become a leading player in Europe”.

About Forbion Capital Partners

Forbion Capital Partners is a Netherlands-based venture capital firm focused on investing in life sciences companies, in particular in world-class drug discovery & development as well as med tech companies addressing substantial unmet medical needs. Forbion’s investment team of eight investment professionals has built an impressive performance track record since the late nineties with successful investments in Rhein Biotech, Crucell, Neutec, Glycart, Borean, Impella, Alantos, Acorda, Fovea and Pangenetics. Current assets under management exceed EUR 375M, split between three active funds and comprising some 25 promising portfolio companies. Finally, Forbion co-manages Biogeneration Ventures, an early stage fund focused on academic spin-outs and seed investments in the Netherlands.

For more information, please visit www.forbion.com.

About Dr. Holger Reithinger

Dr. Holger Reithinger joins Forbion Capital Partners from Global Life Science Ventures’ Munich Office (GLSV). Before GLSV, Holger was a Director at 3i in its German healthcare practice. He started in Venture Capital in 1997 as an Investment Manager at Technologieholding VC GmbH (acquired by the 3i Group in 2000), which at that time was the leading German Venture Capital firm. Prior to this, Holger worked as a product development manager at Biometra/Whatman Plc (now part of GE Healthcare). Holger has served on the boards of numerous life science companies including Epigenomics AG (IPO 2004), MBT AG (assets sold to Medigene AG), 4SC AG (IPO 2005), NeurogesX Inc. (IPO 2007), Fibrex Medical Inc. and Santaris A/S (also a Forbion Portfolio company). He holds a PhD in Biochemistry, which he obtained on protein design under the supervision of Prof. Dr. Arne Skerra (founder of Forbion’s portfolio company Pieris AG); in the department of Prof. Dr. Hartmut Michel (Nobel Laureate 1988) at the Max-Planck-Institute of Biophysics. As an undergraduate, he studied Molecular Biology/Microbial Biology and Biochemistry at the Universities of Heidelberg and Munich.